Pharmaceutical Regulatory decisions from the US Food and Drug Administration featured in the news last with, with a negative advisory panel vote on Aradigm’s antibiotic candidate Linhaliq and news of acceptance of a Biologicals License Application for a Humira (adalimumab) by Novartis subsidiary Sandoz. On the research front, Eiger Pharmaceutical’s pulmonary arterial hypertension drug ubenimex failed. There was strong speculation that Celgene was planning a takeover bid for CAR-T cell therapy specialist Juno Pharma. Also there was disappointment for Johnson & Johnson with the revocation of Johnson & Johnson’s Zytiga patent. 21 January 2018